Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 316,827	$ 228,713
Marketable securities, at fair value	198,563	67,546
Accounts receivable, net	112,130	106,843
Inventories	23,395	29,526
Prepaid assets	12,354	11,547
Assets held for sale	10,050	0
Other current assets	8,189	4,555
Total current assets	681,508	448,730
Property and equipment (net of accumulated depreciation of $109,952 and $92,895, respectively)	109,465	85,873
Operating lease right-of-use assets	102,197	45,786
Intangible assets, net	442,325	120,653
Goodwill	527,115	211,083
Restricted cash	0	21,919
Investment in non-consolidated affiliate	0	29,555
Prepaid lease asset	0	20,229
Other assets	7,168	4,503
Total non-current assets	1,188,270	539,601
Total assets	1,869,778	988,331
Current liabilities
Accounts payable	17,921	24,965
Accrued compensation	38,304	24,727
Accrued expenses and other liabilities	17,796	11,654
Current portion of equipment financing obligations	1,135	2,841
Current portion of operating lease liabilities	6,884	4,967
Current pharma contract liabilities	5,192	4,029
Total current liabilities	87,232	73,183
Long-term liabilities
Convertible senior notes, net	532,483	168,120
Equipment financing obligations	71	967
Operating lease liabilities	72,289	42,296
Deferred income tax liabilities, net	55,475	5,415
Other long-term liabilities	13,951	4,056
Total long-term liabilities	674,269	220,854
Total liabilities	761,501	294,037
Commitments and contingencies (Note 17)
Stockholders’ equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 124,107,500 and 112,075,474 shares issued and outstanding, respectively)	124	112
Additional paid-in capital	1,123,628	701,357
Accumulated other comprehensive (loss) income	(638)	10
Accumulated deficit	(14,837)	(7,185)
Total stockholders’ equity	1,108,277	694,294
Total liabilities and stockholders’ equity	$ 1,869,778	$ 988,331